Understanding the pharmacogenetic basis of developing iatrogenic disorders such as Tardive Dyskinesia (TD) has significant clinical implications. CYP1A2, an inducible gene of the cytochrome P450 family of genes, has been suggested to contribute to the metabolism of typical antipsychotics in subjects with schizophrenia on long-term treatment, and has been considered as a potential candidate gene for development of TD. In this study, we have investigated the significance of CYP1A2 gene polymorphisms in TD susceptibility among chronic schizophrenia sufferers (n ¼ 335) from north India. TD was diagnosed in B29% (96/335) of these subjects. Of the 96 TD positives, 28 had been treated with typical antipsychotics alone, 23 with atypical antipsychotics alone and 45 patients had received both classes of drugs during the course of their illness. Out of the six SNPs tested, CYP1A2*2, *4, *5, *6 were found to be monomorphic in our population. CYP1A2*1C and CYP1A2*1F were polymorphic and were analyzed in the study sample. Since these two allelic variants lead to lesser inducibility among smokers, the smoking status of TD patients was also considered for all subsequent analysis. We observed increased severity of TD among TD-Y smokers, who were carriers of CYP1A2*1C (G4A) variant allele and had received only typical antipsychotic drugs (F(1,8) ¼ 9.203, P ¼ 0.016). No significant association of CYP1A2*1F with TD was observed irrespective of the class of drug they received or their smoking status. However, we found a significant association of CYP1A2*1F with schizophrenia (w 2 ¼ 6.572, df ¼ 2, P ¼ 0.037).
INTRODUCTION
Tardive Dyskinesia (TD) is a movement disorder characterized by choreoathetotic movements, and affects B20% of schizophrenia sufferers on long-term treatment with typical antipsychotics. A genetic predisposition for developing TD among persons suffering from schizophrenia has been observed based on family and twin studies. 1, 2 Advancing age, duration of treatment, female gender and organic brain abnormalities are other well-known risk factors. 3, 4 Several theories have been postulated to explain the pathophysiology of TD, the dopamine overactivity hypothesis being one of them. 5 This hypothesis has received considerable support from pharmacological as well as physiological evidences. [6] [7] [8] [9] Efforts to elucidate the genetic etiology of TD have been made. For example, a large number of association studies to evaluate polymorphisms in genes from the neurotransmitter pathway, including dopamine receptors (D2 and D3), serotonin receptors (HTR2A, HTR2C) and the serotonin transporter (5-HTT) have been carried out. Results from these studies have been inconsistent or untested in additional samples (for review see Basile et al 10 ) with the possible exception of the DRD3 ser9gly polymorphism, which has been supported by a pooled and meta-analysis. 11 Thus, pathophysiological mechanisms underlying TD remain poorly understood. A second large group of genes extensively investigated for association with TD are the cytochrome P450 (CYP450) family of genes.
The CYP450 enzymes are a highly diverse group of heme containing monooxygenases catalyzing a variety of reactions, the most common being hydroxylation. The CYPs catalyze phase I metabolism of drugs, that is elimination of the drug from the circulation, thus influencing the plasma level of the drug. The other factors that affect the plasma level of the drug include absorption from the site of administration and distribution in the body. The CYP1, 2 and 3 family of genes is responsible for metabolism of a majority of xenobiotics. CYP3A4 is responsible for the elimination of B50% of commonly prescribed antipsychotics and antidepressants; CYP2D6 metabolizes approximately 30% and the rest is accounted for by CYP1A2, CYP2C9, CYP2C19 and CYP2E1. 12 Considerable interindividual and interethnic variation in the extent of drug metabolism has been observed. This variation in drug clearance may contribute to the pharmacogenetic differences observed among different patients/populations. Such variation may also explain differential predisposition to iatrogenic disorders such as TD. Associations of the allelic variants causing the poor metabolizer phenotype of CYP2D6 with TD have been reported in several populations, suggesting a possible role of drug disposition in TD susceptibility. 10, 13, 14 CYP1A2 is involved in the metabolism of atypical antipsychotics such as clozapine and olanzapine. It has also been suggested to contribute to the metabolism of typical antipsychotics in subjects with schizophrenia on longterm treatment, and has therefore been considered as a potential candidate gene for susceptibility of TD. Though CYP1A2 is considered to be a low-affinity high capacity metabolic clearance pathway for typical antipsychotics compared to CYP2D6, saturation of the latter during chronic long-term treatment makes CYP1A2 an important enzyme for antipsychotic metabolism. 15 Smoking is a potent inducer of CYP1A2 gene as is evident from the increased rate of caffeine biotransformation. A higher prevalence of smoking B80%
16 has been reported in schizophrenia subjects compared to B25% in the general population. Thus, subjects who are smokers would be expected to have a higher rate of CYP1A2-mediated drug disposition as compared to nonsmokers.
In total, 12 different single-nucleotide polymorphisms (SNPs) in CYP1A2 have been reported (www.imm.ki.se/CYPalleles). However, only two of these SNPs namely CYP1A2*1C (G4A) and CYP1A2*1F (C4A) have been shown to be of functional significance. 17, 18 The CYP1A2*1C (G4A) polymorphism in the upstream region of the human CYP1A2 gene (À3858) results in a significantly reduced induction of this gene among smokers (measured by the rate of caffeine 3-demethylation 17 ). CYP1A2*1F (C4A), an intronic polymorphism was observed in one out of eight healthy volunteers. 18 Thereafter, PCR-RFLP analysis of this polymorphism among nonsmokers and smokers revealed 24 subjects with the CC genotype (10%), 104 with AC genotype (44%) and 108 subjects homozygous for the AA genotype (46%) were identified. A 1.6-fold higher metabolic activity was observed among smokers homozygous for A allele compared with the other genotypes in this category. Nonsmoking subjects did not show any significant differences in the metabolic activity. In view of the above results, Basile et al (2000) investigated whether this mutation contributes to the risk of developing TD in chronic schizophrenia subjects. Abnormal Involuntary Movement Scale (AIMS 19 ) scores were used to assess the severity of TD among 85 schizophrenia subjects. A significantly high mean AIMS score was found among the patients with the CC genotype, 2.7-fold greater than individuals with the AC genotype and 3.40-fold greater than AA genotype. Among smokers homozygous for the CC genotype, a higher mean AIMS score was observed compared to smokers with AC and AA genotypes (4.7-and 5.4-fold greater, respectively). These results lend considerable support to the existing hypothesis that the rate of clearance of the drug from circulation is correlated with the risk for developing TD. However, a study on a group of German subjects with schizophrenia did not observe a significant difference in mean AIMS score between the three genotypic classes. 20 In a second study in subjects of Chinese descent, no association between the C4A polymorphism of CYP1A2 and TD was observed. 21 Though a considerable number of association studies on other candidate genes have been reported in different populations, CYP1A2 polymorphisms have not been investigated extensively in other populations. Considering the high pharmacokinetic significance of this gene in the development of a debilitating disorder such as TD we have analyzed the potential contribution of SNPs (individually or in conjunction) in CYP1A2 gene, to the risk of developing neuroleptic induced TD among schizophrenia subjects from north India using a case-control approach. As a prerequisite, SNPs were validated in our population in 250 healthy individuals. This is the first report of association study of CYP450 polymorphisms with TD among Indians.
RESULTS
Of the 335 subjects with schizophrenia, 96 (28.66%) were diagnosed to have TD based on the AIMS scale. The demographic characteristics of this population are presented in Table 1 . Mean AIMS score of the subjects with TD was 6.5273.482. No statistically significant difference was found in the distribution of males and females between cases and controls or between subjects with TD (TD-Y) and without TD (TD-N). In the TD-Y group, males had higher mean AIMS score as compared to the females (F (1,93) There was no significant difference in mean AIMS scores between the three categories (F(2,92) ¼ 0.88, P ¼ 0.916). Although these data on the class of drugs that the subjects received was available, no reliable information on the drug dosage could be documented.
The prevalence of smoking in subjects with schizophrenia was 23.51%. Since the allelic variants (CYP1A2*1C and CYP1A2*1F) lead to lesser inducibility among smokers, the TD-Y group n ¼ 96 was further subdivided into smokers (n ¼ 31) and nonsmokers (n ¼ 65) for all further analysis. Since the subjects in this study had taken either typical or atypical or both classes of drugs, we have analyzed subjects in each of these groups separately. Thus, we have three distinct patient groups (TD-Y vs TD-N; TD-Y subjects segregated according to the three classes of drugs; and TD-Y smokers only with three classes of drugs, for all statistical analysis).
The baseline allele frequency for each of the six polymorphisms was established by genotyping 250 controls. Of the six tested SNPs, CYP1A2*2, CYP1A2*4, CYP1A2*5, CYP1A2*6 did not show any polymorphism in our study sample. The absence of polymorphism at these four loci in our samples was confirmed by randomly sequencing five samples for each amplicon (data not shown). CYP1A2*1C and CYP1A2*1F were polymorphic and were analyzed further. Their genotypic distributions among the study samples are given in Tables 3 and 4 .
CYP1A2*1C
The allele frequencies for CYP1A2*1C in the control population is G ¼ 0.937, A ¼ 0.0612 (PIC ¼ 0.1763). The distribution of the genotypes in the control population was not in Hardy-Weinberg equilibrium (HWE) (w 2 ¼ 5.33, df ¼ 1, P ¼ 0.0250). However, the observed genotypic frequencies did not deviate from those expected under HWE for subjects with and without TD and on different drug regimes (P40.05). There was no statistically significant difference between the distribution of genotypic frequencies between the TD-Y vs TD-N group and TD-Y vs TD-N categorized based on the different class of drugs (P40.05; Tables 2 and 3 ).
The mean AIMS scores among TD-Y subjects who were smokers with different genotypes were compared. No 2-2 homozygotes were observed among smokers. Among the TD-Y subjects who had been on typical antipsychotics and were smokers, the mean AIMS score was significantly higher for individuals heterozygous for the variant allele (13.0071.414 vs 7.5674.22; P ¼ 0.016; Table 4 ). Since the number of samples under each genotype category was negligible for TD-Y smokers under the atypical drug treatment ANCOVA was not performed. When we considered the subjects who received typical drugs along with those who received both classes of drugs, no significant difference was observed (P ¼ 0.570; Table 4 ).
CYP1A2 is also inducible by a variety of other environmental agents apart from smoking. We analyzed whether this polymorphism has an overall significance in TD per se. Among subjects who received typical antipsychotic drugs, heterozygous carriers of the variant allele (1-2) had a slightly higher mean AIMS score (9.7573.86 vs 6.2173.48) and was significantly different from the homozygous wild type (1-1; Subjects classified according to the class of drugs they had taken either atypical or atypical anitpsychotics or both the drug types during the course of illness.
Association of CYP1A2 polymorphisms with Tardive Dyskinesia AK Tiwari et al P ¼ 0.030; Table 5 ). However, no significant difference in the mean AIMS score was observed when subjects in the typical antipsychotic group and those who received both classes of drugs were combined (P ¼ 0.166). Similarly, the mean AIMS score was not significant for the subjects who had received only atypical drugs across the two genotypic categories (P ¼ 0.318; Table 5 ).
CYP1A2*1F
The baseline allele frequency of CYP1A2*1F (PIC ¼ 0.4998) in the control population studied was C ¼ 0.488 and A ¼ 0.512. The genotypes were in HWE in the control population (w 2 ¼ 3.4885, df ¼ 1, P ¼ 0.10). The observed genotypic frequencies did not deviate from those expected under HWE for subjects with and without TD and those on different drug regimes (P40.05). The distribution of genotypic frequencies between the TD-Y vs TD-N group and TD-Y vs TD-N categorized based on different classes of drugs was not statistically significant (P40.05; Tables 2 and 3) .
A comparative analysis of severity of TD among smokers with different genotypes was also carried out. There was no significant association between the allelic state of the individual and the AIMS score for the subjects who were smokers and were under typical antipsychotic medication (P ¼ 0.101; Table 4 ). The SNP was not significantly associated with TD even when the entire group (all subjects receiving typical antipsychotics) was considered (P ¼ 0.425; Table 5 ). Similar nonsignificant results were obtained when the subjects who received typical antipsychotics were considered along with those who received both classes of drugs (P ¼ 0.737; Table 5 ) as well as for subjects who had received only atypical drugs (P ¼ 0.929; Table 5 ). Haplotype frequencies of CYP1A2*1C and CYP1A2*1F (for TD-Y and TD-N subjects who received typical or atypical drugs) were We also investigated whether the above two polymorphisms are a risk factor for the development of schizophrenia. It was found that the genotypic distribution of CYP1A2*1C is not statistically significant between the controls (age and sex matched) and subjects with schizophrenia (w 2 ¼ 2.405, df ¼ 2, P ¼ 0.301). Genotypic distribution of CYP1A2*1F was however statistically significant at 5% level (w 2 ¼ 6.572, df ¼ 2, P ¼ 0.037; Table 6 ). Haplotypic frequencies calculated and compared between cases and controls did not show association (P ¼ 0.147). A strong linkage disequilibrium was observed between CYP1A2*1C and CYP1A2*1F (D 0 ¼ 0.89; r 2 ¼ 0.05).
DISCUSSION
The present study was undertaken to establish association, if any, of six functional SNPs in CYP1A2 gene with TD, among schizophrenia subjects from north India. Since CYP1A2 is one of the major genes involved in metabolism of xenobiotics and TD is an iatrogenic disorder developing in about 20-30% of all schizophrenia subjects on long-term treatment with typical antipsychotics, study of SNPs in this gene has major pharmacogenetic implications. This is the first report on both the genetics of TD as well as SNPs in CYP1A2 gene from this ethnically distinct population. The severity of TD has also been observed to increase with age in conformity with other reports. 4, 11, 22 However, severity of TD was higher among males compared to females in our study, which is in contrast to other reports. 23, 24 This may be due to sampling variation or may reflect a variation unique to Indian population.
Of the 96 TD positive subjects, while 28 had received only typical antipsychotics, 23 had received only atypical antipsychotic drugs. Although the mean AIMS scores between these two groups of TD patients were not significantly different, the duration of schizophrenia in the former group 
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AK Tiwari et al was higher. However, we would be cautious in interpreting these results due to the nonavailability of the drug dosage in our study sample. Our observation of a comparable number of subjects developing TD while on only atypical antipsychotic medication is notably different from most other available reports on drug induced TD, where TD has been shown to be largely induced by typical antipsychotic drugs. 10 As far as atypical antipsychotic drugs are concerned, weight gain and not TD has been one of the major side effects documented. 10 Such a difference between most of the other reports and the present study may reflect basic genetic difference(s) underlying development of TD among different ethnic groups. Alternately, use of atypical antipsychotic drugs in most countries may be rather limited due to cost and therefore there may have been limited scope to evaluate this effect.
The absence of polymorphism at four SNPs (*2, *4, *5, *6) in the CYP1A2 gene in our population is different from the available report in French population. 25 However, it may be noted that the allele frequency of the SNPs were considerably low (0.5-1%) even in that population. This may indicate either a recent evolution of these SNPs in the human genome (considering the highly adaptive nature of drug metabolism 26 ) or may reflect the highly conserved nature of this gene. However, the reported highly variable activity of this gene (10-to 30-fold 27 ) may be due to polymorphism(s) in the conserved domains (3-Methylchol anthrene elements) in the upstream region of the gene as suggested recently. 28 A very low frequency of polymorphism has been observed in CYP1A2*1C (PIC ¼ 0.1763) in this 3-MC element in our study sample. This is similar to the Egyptian population 29 but significantly different from that reported in Japanese population. 17 Consequently, absence of association of this SNP with TD in our study seems in order. Since no other reports on association of this SNP with TD are available, comparisons are not possible. The severity of TD among subjects who were smokers as well as treated only with typical antipsychotic drugs (n ¼ 11) was significantly higher in subjects carrying the single copy of the variant (13.0071.414 vs 7.5674.22; P ¼ 0.016). This could be explained on the basis of differential inducibility in the presence of the variant allele. However, since only two such heterozygous individuals were observed (Subject-1 AIMS score ¼ 12; Subject-2 AIMS score ¼ 14) we would be cautious in giving any weightage to this observation. A study having a larger sample size is warranted for conclusive inference. Increased severity was also observed when the complete TD-Y group (both smokers and nonsmokers) treated with only typical antipsychotics (n ¼ 28) was considered (9.7573.86 vs 6.2173.48; P ¼ 0.030). However, this was contributed by the same two heterozygous (smokers) individuals mentioned above.
The allele frequency of CYP1A2*1F in our study sample is slightly different from those reported for Caucasian populations. 15, 18, 29 However, it is similar to the frequency reported for African Americans. 15 Association of TD with CYP1A2*1F had earlier been reported by Basile et al. 15 However, Schultze et al 20 failed to replicate this finding. In our population also we did not observe any significant association between TD and *1F. The lack of association could be attributed to several factors: (a) Differing genetic backgrounds as partly evident from differing allele frequencies in this gene; (b) The CYP1A2*1F (and also*1C) gene is inducible by smoking but smoking was not prevalent among schizophrenia subjects in our samples (however, CYP1A2 is induced by a variety of other substances such as glucosynolates present in cruciferous vegetable and charboiled meat); and (c) The sample size is small and thus reduced statistical power to detect any association if the gene is of minor effect (Table 2) . However, since the sample characteristics with specific reference to prevalence of smoking were notably different from the previous reports, 15, 20 any direct comparison between their observation and this study on ethnically distinct Indian population is inappropriate.
The mean AIMS score in TD-Y individuals on medication only with typical drugs and who were homozygous for the variant allele (AA) of *1F was higher in comparison to other genotypic categories but was not statistically significant (Table 5 ). Similar trend was observed among smokers on typical drug treatment only (Table 4) . However, as in the case of CYP1A2*1C the number of individuals in each of the genotypic categories being low, it is difficult to come to any reliable conclusion.
As in the case of individual SNPs, no association was observed between CYP1A2*1C and CYP1A2*1F haplotypes with TD. Although a high linkage disequilibrium was observed between the two markers, CYP1A2*1C SNP was not found to be associated with schizophrenia, unlike CYP1A2*1F SNP. This may be due to the low polymorphism at CYP1A2*1C making it an uninformative marker. In addition, the correlation coefficient r 2 , which represents whether both SNPs would be associated with the disease, was very low in our study (r 2 ¼ 0.05). The observed marginal association of CYP1A2*1F (located at 15q21) with schizophrenia may not be totally unexpected. Chromosome 15q13-15 has been found to be associated with schizophrenia in genome wide scans [30] [31] [32] although the criteria for linkage were fulfilled in only one study using a subtype Periodic Catatonia (15q15 at position 35.3 cM, LOD score ¼ 3.57, P ¼ 2.6 Â 10 À5 ). ). This linkage has been replicated in several other populations including African Americans, 31 Germans, 32 Southern African Bantu families 34 and Taiwanese. 35 Several other studies have also pointed towards this region as being of significance for psychiatric disorders. Further, psychoses resembling schizophrenia in Angelman syndrome and Prader Willi syndrome (15q11-13) have been reported to be due to abnormal genome imprinting and in Marfan syndrome (15q21), due to mutations in the fibrillin gene. Several genes present in this region are expressed in the brain, including tight junction protein (TJP1) and CKTSF1B1, the human homologue of DRM/ GERMLIN, a secretory granule neuroendocrine protein.
CYP1A2 is located at 15q22 with two other cytochrome p450 genes (CYP1A1 and CYP11A) in the vicinity of Nicotinic receptors CHRNA3, CHRNA5, CHRNB4, localized at 15q24. Although CYP1A2 by itself has never been implicated in pathogenesis of schizophrenia the neighboring loci as mentioned above have all been implicated. The polymorphism at CYP1A2*1F we have studied may by itself predispose to schizophrenia or it may be in linkage disequilibria with flanking loci. CYP1A2 mRNA has been detected in the rat brain (cortex, cerebellum, brain stem, thalamus, hippocampus, striatum 36 ). Its presence in brain tissues probably plays a role in protecting the brain from xenobiotics and differential activity of the gene in vivo may be responsible for differential susceptibility. The positive association observed may be due to one of these reasons. Further, either different loci might be important for disease susceptibility in different populations or the observed association might be a false positive result. However, the latter appears highly unlikely since the neighboring loci have been linked to schizophrenia in several independent studies and our sample size is considerably large eliminating such type 1 errors. On the other hand, absence of any detectable association of CYP1A2*1F with TD in our study may reflect a type 2 error, caused due to small number of smokers among TD cases and thus reduced statistical power. Therefore, we may conclude that CYP1A2*1F is weakly associated with schizophrenia and CYP1A2*1C shows a trend of increased severity of TD in subjects who are smokers and have received only typical antipsychotic drugs. 38 was used for interviewing. Consensus diagnoses were established by two psychiatrists/psychologists using DSM IV criteria. Inter-rater reliability between the Indian and US research staff was examined throughout the study (k40.80 38 ). Schizophrenia subjects (n ¼ 335) diagnosed according to the DSM IV criteria (mentioned above) were included in this retrospective cross-sectional study. All 335 subjects were evaluated for TD by three trained research personnel (a psychiatrist and two psychologists) and consensus diagnosis established using the AIMS scale. Patients with overall two mild ratings or at least one moderate or high rating in any of the categories on AIMS scale (a single evaluation) was used as the threshold for diagnosis of TD, following the RDC-TD. 39 The Simpson-Angus Rating Scale (SARS) 40 was used for additional assessment. Other inclusion criteria were the availability of antipsychotic treatment history (for at least 3 months). Smoking status was documented by asking the proband and family members. Only those individuals who provided written informed consent and who were less than 60 years of age were included in this study.
MATERIALS AND METHODS

Controls
Age, sex and ethnicity matched healthy individuals (n ¼ 250) were recruited from the collaborating hospitals and the University Health Center. The controls and their families had no previous history of any neuropsychiatric disorder.
Genetic Analysis
Peripheral venous blood (10 ml) was drawn from all participating subjects and used for DNA isolation. Genomic DNA was isolated using the conventional phenol chloroform extraction method. 41 Polymerase chain reaction was used for the amplification of specific regions of CYP1A2 gene (AH002667). Information on SNPs to be evaluated in this study was obtained from the CYPallele nomenclature web site www.imm.ki.se/CYPalleles. Six sets of primers to amplify the specific regions encompassing the SNPs to be evaluated were designed using Primer ver 1.0. Of the six SNPs, four (CYP1A2*2, *4, *5, *6) were evaluated by SnaPshot method (Table 7) using commercial facility at LabIndia, New Delhi, India. Two SNPs (CYP1A2*1C and CYP1A2*1F) were assayed by PCR-RFLP approach. Primers used for amplification of CYP1A2*1C were F5 0 -GCT ACA CAT GAT CGA GCT ATA C-3 0 and R5 0 -CAG GTC TCT TCA CTG TAA AGT TA-3 0 . 17 Briefly, the PCR was performed in a total reaction volume of 20 ml containing 100 ng of DNA template, 200 mM dNTPs, 0.5 mM of each primer, 0.5 U of Taq polymerase (Roche) and 1 Â PCR reaction buffer. Cycling conditions were initial denaturation at 951C for 5 min followed by 35 cycles of 951C for 45 s, 561C for 45 s, 721C for 1 min and final extension at 721C for 7 min. The resulting 596-bp segment was digested with DdeI and resolved on a 3% ethidium bromide containing agarose gel. The wild-type allele gave an undigested band of 596 bp, and the digested product was resolved into 464 and 132 bp band. The 520-bp region in intron I containing CYP1A2*1F was amplified using the primers F 5 0 -TGG AGT GGT CAC TTG CCT CT-3 0 and R 5 0 -CTG GCT CAT CCT TGACAG T-3 0 . The cycling conditions were initial denaturation at 951C for 5 min, followed by 35 cycles of 951C for 30 s, 581C for 30 s, 721C for 45 s and final extension at 721C for 5 min. The PCR products were digested with 1 U of Bsp120I restriction endonuclease. The allele A showed as an undigested band at 520 bp, the presence of allele C resulted in a 373 and a 147 bp band. The digestion products were resolved on a 3% ethidium bromide containing agarose gel. Complete digestion was observed in all the samples for both the SNPs. In addition, samples with known genotypes were included in each set of digestion to ensure that the observed genotypes were not due to partial/incomplete digestion.
SnaPshot PCR
PCR reactions were performed with approximately 100 ng of genomic DNA. Briefly, 25 ml reactions were set up with 1.5 mM MgCl 2 , 100 mM of each of dATP, dCTP, dGTP and dTTP, 0.5 U of AmpliTaq Gold (ABI) and 20 pmol each of forward and reverse primers. The cycling conditions were initial denaturation at 961C for 13 min followed by 40 cycles of denaturation 951C for 10 s, annealing and amplification at 601C for 1 min. The final extension was carried out at 721C for 30 min.
SnaPshot reactions
For removal of excess PCR primers and dNTPs, the PCR products were digested with 0.25 U of Exonuclease I (Epicenter) and 0.5 U of Shrimp Alkaline Phosphatase (MBI Fermentas) at 371C for 2 h, followed by inactivation of Exonuclease I and SAP at 801C for 15 min. Subsequently, SnaPshot reactions were set up using 2 ml of digested PCR products, 1.25 ml of SnaPshot ready reaction mix (ABI), 0.5 ml of 5 Â sequencing Buffer, 0.25 mM concentration of SnaPshot primer (0.25 uM of each primer in case of multiplex reactions) and MilliQ water to make up the reaction volume to 5 ml. The cycling conditions were 25 cycles at 961C for 10 s, 501C for 5 s and 601C for 30 s. After the reactions were completed, 0.5 U of Calf Intestinal Alkaline Phosphatase (MBI Fermentas) was added to each reaction and incubated at 371C for 1 h, followed by inactivation of CIP at 801C for 15 min. For running the products in ABI 3100 Genetic Analyzer, 2 ml of each of SnaPshot products (for multiplex injection) were mixed with 8 ml of Hi Di Formamide (ABI), denatured at 951C for 5 min and snapchilled on ice. The samples were then analyzed using Run Module SNP22_POP4, Dye set E5, Pop4 polymer and 22 cm Capillary Arrays.
Data analysis
The data were first analyzed with GeneScan Analysis Software 3.7. Subsequently, the GeneScan data were analyzed with Genotyper Software 3.7 for automated allele calling and generation of tables.
Statistical Analysis
Frequencies of each of the SNPs evaluated in this study were calculated for both the healthy volunteers as well as subjects with schizophrenia. Hardy-Weinberg equilibrium was tested for the observed genotypes using w 2 test. The gender distribution was compared using w 2 test and the mean age among different groups such as TD positive (TD-Y), TD negative (TD-N) and controls was compared using t-test.
Association of individual SNPs was tested using a w 2 test. All statistical tests were carried out using the Statistical Package for Social Sciences (SPSS) version 11.0. The mean AIMS score was compared between each of the genotypic classes using analysis of covariance (ANCOVA), with age as a covariate. Levene test for homogeneity of variance was carried out to check the assumption of equal variance among each genotypic class, normal distribution of genotypic categories was tested using Kolmogrov-Smirnov Z test. Power calculation was carried out based on mean AIMS score and sample sizes, with alpha set to 0.05. In case of violation of any of the assumptions of ANCOVA Kruksal Wallis H test was performed. Power calculations were also carried out for casecontrol analysis based on differences in the allele frequency between cases and controls and sample size [PAWE 42, 43 ]. Haplotype frequencies were calculated using PHASE ver2.0.2 44, 45 and haplotypic association was tested using CLUMP. 46 Linkage disequilibrium between the markers was calculated using EMLD (www.linkage.rockefeller.edu).
